gastroenteritis glp 1 GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment Gastrointestinal adverse events associated with

Unrealised Expectations Despite progress, several anticipated 2025 milestones did not come to fruition: Regulatory progress stalled: FDAs obesity drug guidance, published in draft form in January 2025, remains unfinalised, whilst EMA has yet to update its 2016 guideline

Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular disease

This emerging option has shown potential benefits not only for weight management []

I'm sharing my insights on potential risks, from nausea & constipation to more serious concerns like thyroid issues or pancreatitis

muciniphila are interesting candidates as they can potentially reach and interact with the epithelial barrier

Clinically informed ingredients